A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens

摘要: Aim: Many hepatitis C virus regimens are unlikely to be compared head head. In more difficult treat populations where there is no standard of care, trials single arm. We describe a flexible meta-analysis platform in this setting. Methods: Our literature based. illustrate our methodology and show how inference can extended single-arm trials. Results: As an example, the arm setting, regimen with response rates 84, 72 54% genotype 1a across treatment naive, previous partial responders null responders, respectively, would have 95% probability superiority IFN-α + RBV TPV. Conclusion: This rigorous approach comparative effectiveness that accounts for varying patient plans incorporation emerging treatments.